Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies-Reference-Cited by-全球学者库

Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies

Published:2024-01-19 Issue:6680 Volume:383 Page:
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Martin-Alonso Carmen¹²^ORCID,Tabrizi Shervin¹³⁴⁵^ORCID,Xiong Kan³^ORCID,Blewett Timothy³,Sridhar Sainetra³^ORCID,Crnjac Andjela³^ORCID,Patel Sahil¹³⁶^ORCID,An Zhenyi³,Bekdemir Ahmet¹,Shea Douglas³^ORCID,Wang Shih-Ting¹^ORCID,Rodriguez-Aponte Sergio¹⁷^ORCID,Naranjo Christopher A.¹,Rhoades Justin³^ORCID,Kirkpatrick Jesse D.¹²^ORCID,Fleming Heather E.¹^ORCID,Amini Ava P.⁸^ORCID,Golub Todd R.³⁵⁹^ORCID,Love J. Christopher¹³¹⁰^ORCID,Bhatia Sangeeta N.¹²³¹¹¹²^ORCID,Adalsteinsson Viktor A.³^ORCID

Affiliation:

1. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

2. Harvard-MIT Division of Health Sciences and Technology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

3. Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

4. Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.

5. Harvard Medical School, Boston, MA 02115, USA.

6. Division of Pulmonary and Critical Care, Department of Medicine, Massachusetts General Hospital, Boston, MA 02124, USA.

7. Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

8. Microsoft Research, Cambridge, MA 02142, USA.

9. Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

10. Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

11. Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

12. Department of Medicine, Brigham and Women’s Hospital, Boston, MA 02115, USA.

Abstract

Liquid biopsies enable early detection and monitoring of diseases such as cancer, but their sensitivity remains limited by the scarcity of analytes such as cell-free DNA (cfDNA) in blood. Improvements to sensitivity have primarily relied on enhancing sequencing technology ex vivo. We sought to transiently augment the level of circulating tumor DNA (ctDNA) in a blood draw by attenuating its clearance in vivo. We report two intravenous priming agents given 1 to 2 hours before a blood draw to recover more ctDNA. Our priming agents consist of nanoparticles that act on the cells responsible for cfDNA clearance and DNA-binding antibodies that protect cfDNA. In tumor-bearing mice, they greatly increase the recovery of ctDNA and improve the sensitivity for detecting small tumors.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Link

https://www.science.org/doi/pdf/10.1126/science.adf2341

Reference77 articles.

1. Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies

2. Screening for Fetal Chromosomal Abnormalities

3. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease

4. Current and future perspectives of liquid biopsies in genomics-driven oncology

5. Circulating Cell-Free DNA Enables Noninvasive Diagnosis of Heart Transplant Rejection

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surpassing sensitivity limits in liquid biopsy;Science;2024-01-19